GLAXOSMITHKLINE and Sanofi have signed an agreement with the European Commission to supply 300 million doses of the Covid-19 vaccine, once it is approved. The news was published on the GSK website today.
A phase 3 study is planned to start by the end of 2020 and the approval for the final dosage can be requested at the start of 2021. Sanofi and GSK are leveraging on the manufacturing of the antigen while aiming to produce up to one million doses a year.
- The agreement will enable all the Member Stated of the European Union to purchase the vaccine against Covid-19.
- The Member States can donate the doses to the middle-income or developing countries at their discretion.
- The antigen and vaccine doses will be prepared in European countries, strengthening GSK and Sanofi’s industrial units in Italy, Belgium, France, and Germany.
- The companies have announced phase 1/2 of the clinical trial on September 3rd.
The final agreement is following up on the announcement made on July 13 by the companies to show concerns for the safety of the European population against Covid-19.